-transparent.png){kind=logo}
One hundred and forty-four patients with advanced renal cell cancer were evaluated for objective response to single-agent treatment with megestrol acetate, VP-16-213, cyclophosphamide, or dianhydrogalactitol. In view of the low order of response observed, these agents do not appear to be effective in the treatment of metastatic renal cell cancer. Performance status and a relatively long interval from onset of primary symptoms to study entry were the most favorable prognostic variables affecting time to progression and survival for patients in this study.
Related Publications
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
September 1976,
Cancer treatment reports,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
November 1976,
Cancer treatment reports,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
January 1981,
Oncology,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
September 1986,
Gan to kagaku ryoho. Cancer & chemotherapy,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
December 1987,
Cancer,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
April 1981,
Onkologie,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
October 1985,
Gynecologic oncology,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
January 1984,
Cancer chemotherapy and pharmacology,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
January 1979,
Cancer,
R G Hahn, and
M Bauer, and
J Wolter, and
R Creech, and
J M Bennett, and
G Wampler
February 1982,
American journal of clinical oncology,
